Cibc World Market Inc. lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 52.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,625 shares of the life sciences company’s stock after purchasing an additional 6,773 shares during the period. Cibc World Market Inc.’s holdings in Illumina were worth $5,371,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. BlackRock Inc. purchased a new position in Illumina in the second quarter valued at about $3,374,423,000. Primecap Management Co. CA purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $617,981,000. Ninety One UK Ltd increased its stake in shares of Illumina by 37,920.0% during the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after purchasing an additional 1,356,397 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of Illumina in the 2nd quarter worth approximately $358,652,000. Finally, Wellington Management Group LLP raised its holdings in shares of Illumina by 190.1% in the 2nd quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock worth $318,767,000 after purchasing an additional 1,188,004 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Leerink Partners upped their price target on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Evercore reissued an “underperform” rating on shares of Illumina in a report on Friday, October 30th. Jefferies Financial Group set a $235.00 target price on shares of Illumina and gave the stock a “hold” rating in a research note on Monday, November 16th. Weiss Ratings lowered shares of Illumina from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $243.72.
Insider Activity at Illumina
In related news, Director Keith Meister sold 231,433 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $238.52, for a total transaction of $55,201,399.16. Following the completion of the transaction, the director owned 538,917 shares of the company’s stock, valued at approximately $128,542,482.84. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 1,201,292 shares of company stock valued at $270,151,290 in the last three months. 2.90% of the stock is currently owned by company insiders.
More Illumina News
Investors following ILMN have been watching these news items:
- Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result highlights the company’s data and AI capabilities, although the financial impact is not yet clear. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
- Neutral Sentiment: Bernstein reportedly maintained a Hold rating, suggesting a cautious stance rather than a new positive catalyst. Illumina Gets a Hold from Bernstein
- Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?
Illumina Stock Performance
Shares of ILMN opened at $192.82 on Friday. The stock’s 50-day simple moving average is $248.27 and its 200 day simple moving average is $181.05. The stock has a market capitalization of $29.15 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the previous year, the firm earned $1.34 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Research analysts forecast that Illumina, Inc. will post 5.43 EPS for the current fiscal year.
About Illumina
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
See Also
- Five stocks we like better than Illumina
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
